* Helius Medical Technologies Inc is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2024
* The Newtown Pennsylvania-based company is expected to report a 17.6% increase in revenue to $130.5 thousand from $111 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Helius Medical Technologies Inc is for a loss of $3.87 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 3.8% in the last three months.
* Wall Street's median 12-month price target for Helius Medical Technologies Inc is $15.00, above its last closing price of $1.63.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -4.05 -3.77 -1.47 Beat 61
Sep. 30 2023 -6.00 -5.49 Beat 8.5
Jan. 1 0001 -6.00 -5.83 -3.00 Beat 48.6
Mar. 31 2023 -5.48 -5.50 -4.50 Beat 18.2
Dec. -6.64 -6.50 -8.50 Missed -30.8
31 2022
Jan. 1 0001 -10.52 -10.50 -1.50 Beat 85.7
Jun. 30 2022 -56.00 -56.00 -48.50 Beat 13.4
Mar. 31 2022 -56.50 -56.50 -57.50 Missed -1.8
This summary was machine generated May 10 at 22:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments